“Human undifferentiated neural progenitor stem cells (NPC) alleviate motor dysfunction, repair morphological damage and extend life span in a spastic Han Wistar model of cerebellar ataxia” poster presented at the 2020 American Society of Cell & Gene Therapy Annual Meeting.
“In Vitro And In Vivo Characterization Of Clinical Grade Human Undifferentiated Neural Progenitor Stem Cells (Npc) For Treatment Of Neurodegenerative Diseases” poster presented at the 2020 International Society for Stem Cell Research Annual Meeting.
Celavie Biosciences CEO Sandy Solomon sat down with Proactive’s Christine Corrado at the BIO CEO & Investor Conference in New York. The California-based company is developing regenerative stem cell therapies to treat Parkinson’s disease and other central nervous system disorders.
Sandy Solmon wears several hats, she leads a private, emerging medical technology company that develops stem cell-based regenerative therapies for the treatment of CNS disorders and she is CEO, chief innovator, and founder of Sweet Street Desserts, the world’s largest manufacturer of frozen gourmet desserts. From R&D to regulations, she discusses how running a global food company translates to an emerging biotech company.
Celavet Inc. Plans Submission of Equine Tendinitis Study to FDA’s Center for Veterinary Medicine and Announces Ashlee E. Watts, DVM, PhD, DACVS as Principal Investigator
OXNARD, Calif.–(BUSINESS WIRE)–Celavet Inc., a regenerative medicine company developing stem cell-based therapies for the treatment and prevention of orthopedic injuries and diseases in large and small animals, and a subsidiary of Celavie Biosciences, LLC, today announced Ashlee E. Watts, DVM, PhD, DACVS as principal investigator for a new equine tendinitis study being submitted to the FDA’s Center for Veterinary Medicine (CVM).
OXNARD, Calif.–(BUSINESS WIRE)–Celavie Biosciences, LLC, a company working to improve lives and restore hope by advancing innovations in CNS diseases with regenerative stem cell-based therapies, today announced that the Company will give a corporate presentation at the April 2020 Virtual Investor Summit, taking place online from April 22-23, 2020. Sandy Solmon, the Company’s President and Chief Executive Officer, will also give a corporate overview and update on recent momentum at Celavet Inc., a subsidiary of Celavie Biosciences that develops stem cell-based therapies for the treatment and prevention of orthopedic injuries and diseases in large and small animals. The presentation will take place on Thursday, April 23, 2020 at 1:00pm ET, followed by a live Q&A session with registered investors and other conference attendees.
Celavie Biosciences Presented Five-Year Follow-Up Data in Parkinsonian Patients at the World Stem Cell Summit
CEO Sandy Solmon to Present on Celavie’s Stem Cell Therapies at Upcoming Conferences in New York and Barcelona
OXNARD, CA – January 22, 2020 – Celavie Biosciences, LLC, a company working to improve lives and restore hope by advancing innovations in CNS diseases with regenerative stem cell-based therapies, today announced their presentation of a poster, titled “Five year follow-up on the first-in-human transplantation of undifferentiated stem cells into Parkinsonian patients reveals no adverse effects with improvement in motor function or arrest of the disease progression in five out of seven patients,” at the Phacilitate Leaders World and World Stem Cell Summit, held January 21-24 in Miami, Florida.